Mendus (OMX: IMMU)

Last close As at 23/11/2024

SEK8.47

−0.77 (−8.33%)

Market capitalisation

SEK427m

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology and currently has two lead, cell-based, off-the-shelf therapies for haematological and solid tumours.

IO is a frenetic pharmaceutical development area with many clinical combination studies being conducted by pharmaceutical and biotech companies. Investors should expect relatively rich news flow from this subsector over the next few years.

Latest Insights

View More

Healthcare | Update

Mendus — Broad progress across the pipeline

Healthcare | edison tv

Mendus – executive interview

Healthcare | Flash note

Mendus — Collaboration unveils path forward for ilixadencel

Healthcare | Flash note

Mendus — Recent clinical data highlight vididencel’s potential

Mendus_resized

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Alex Karlsson-Parra

    CSO

  • Erik Manting

    CEO

  • Jeroen Rovers

    CMO

  • Leopold Bertea

    CTO

  • Lotta Ferm

    CFO

Balance Sheet

Forecast net cash (SEKm)

89

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 12.9 15.6 (20.7)
Relative 18.7 19.6 (31.4)
52 week high/low SEK14.5/SEK7.5

Financials

Mendus is developing lead candidate vididencel, a cell-based vaccine, as a maintenance therapy for the prevention or delay of tumour recurrence (currently being assessed in two indications). Encouraging survival data were reported for the ADVANCE II trial (AML) in December 2023, showing a potentially competitive profile over standard of care and the only approved AML maintenance drug, Onureg. Management is planning to maximise the potential of vididencel with the CADENCE study in combination with Onureg (enrolment commenced in September 2024). Vididencel is also being assessed in the Phase I ALISON trial (ovarian cancer). In June 2024, Mendus announced that the primary goal for ALISON had been met; long-term survival data will be presented in Q424. The company’s second clinical asset, ilixadencel, is being developed as an intratumoral immune primer and is in preparations to start a Phase II trial for the treatment of soft tissue sarcomas. Net cash at end-Q224 was SEK130.2m, which should fund Mendus into Q325.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (fd) (öre) P/E (x) P/CF (x)
2022A 3.4 (128.8) (138.8) (1392.0) N/A N/A
2023A 29.6 (94.3) (101.6) (440.0) N/A N/A
2024E 4.2 (135.6) (141.8) (303.2) N/A N/A
2025E 0.0 (117.7) (124.0) (246.2) N/A N/A

Research

edison tv

Healthcare

Executive interview with Erik Manting PhD, CEO of Mendus

Flash note

Healthcare

Mendus — Gross proceeds of c SEK69m to advance pipeline

Flash note

Healthcare

Mendus — Regulatory green light for CADENCE trial

Flash note

Healthcare

Mendus — Stars align for CADENCE combination trial

Mendus_resized

Flash note

Healthcare

Mendus — Poised for an active 2024

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free